Vir Biotechnology, Inc.
General ticker "VIR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $970.7M (TTM average)
Vir Biotechnology, Inc. follows the US Stock Market performance with the rate: 49.2%.
Estimated limits based on current volatility of 3.4%: low 11.09$, high 11.86$
Factors to consider:
- Total employees count: 367 (-10.0%) as of 2025
- US accounted for 15.5% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Net losses, Limited commercialization history, Need substantial additional funding, Labor/talent shortage/retention, Strategic risks and growth management
- Price in estimated range
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [4.85$, 11.54$]
- 2026-12-31 to 2027-12-31 estimated range: [4.43$, 10.64$]
Financial Metrics affecting the VIR estimates:
- Positive: with PPE of -1.9 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -47.18 <= 0.28
- Negative: negative Net income
- Positive: Investing cash flow per share per price, % of 37.38 > -0.64
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term VIR quotes
Long-term VIR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $86.18MM | $74.20MM | $68.56MM |
| Operating Expenses | $770.49MM | $661.37MM | $547.88MM |
| Operating Income | $-684.30MM | $-587.16MM | $-479.33MM |
| Non-Operating Income | $56.11MM | $64.06MM | $41.56MM |
| R&D Expense | $579.72MM | $506.50MM | $455.97MM |
| Income(Loss) | $-628.19MM | $-523.11MM | $-437.77MM |
| Taxes | $-13.08MM | $-1.15MM | $0.22MM |
| Net Income(Loss)* | $-615.06MM | $-521.96MM | $-437.99MM |
| Stockholders Equity | $1,590.24MM | $1,150.38MM | $765.28MM |
| Assets | $1,919.06MM | $1,398.81MM | $1,002.82MM |
| Operating Cash Flow | $-778.78MM | $-446.35MM | $-391.78MM |
| Capital expenditure | $21.57MM | $7.30MM | $4.83MM |
| Investing Cash Flow | $164.63MM | $499.37MM | $310.37MM |
| Financing Cash Flow | $7.48MM | $4.39MM | $3.79MM |
| Earnings Per Share** | $-4.59 | $-3.83 | $-3.16 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.